AI assistant
Sending…
INCYTE CORP — Director's Dealing 2026
Feb 23, 2026
30371_dirs_2026-02-23_83c51ec4-a5fb-407a-9f54-5fdf5f910ea3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: INCYTE CORP (INCY)
CIK: 0000879169
Period of Report: 2026-02-19
Reporting Person: CAGNONI PABLO J (President, R&D)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-02-19 | Common Stock | M | 13093 | $61.76 | Acquired | 247893 | Direct |
| 2026-02-19 | Common Stock | M | 5575 | $61.18 | Acquired | 253468 | Direct |
| 2026-02-19 | Common Stock | S | 18668 | $100.91 | Disposed | 234800 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-02-19 | Employee Stock Option (right to buy) | $61.76 | M | 13093 | Disposed | 2033-07-13 | Common Stock (13093) | Direct |
| 2026-02-19 | Employee Stock Option (right to buy) | $61.18 | M | 5575 | Disposed | 2034-01-17 | Common Stock (5575) | Direct |
Footnotes
F1: This includes an aggregate of 229,661 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
F2: The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
F3: Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years.
More from INCYTE CORP
Proxy Solicitation & Information Statement
2026
May 27
Major Shareholding Notification
2026
May 14
Major Shareholding Notification
2026
May 11
Major Shareholding Notification
2026
Apr 30
Annual Report
2026
Apr 28
Proxy Solicitation & Information Statement
2026
Apr 28
Proxy Solicitation & Information Statement
2026
Apr 28
Interim / Quarterly Report
2026
Apr 28
Regulatory Filings
2026
Apr 28
Regulatory Filings
2026
Mar 30